title: Efficacy of combined photodynamic therapy and sub-Tenon's capsule injection of triamcinolone acetonide for age-related macular degeneration.
abstract: OBJECTIVE
  To evaluate the efficacy of combined photodynamic therapy (PDT) and sub-Tenon's capsule injection of triamcinolone acetonide (TA) for the treatment of choroidal neovascularization (CNV) in age-related macular degeneration (AMD) at 1-year follow-up.
  
  
  METHODS
  A total of 117 eyes with subfoveal CNV caused by AMD were included. Sixty-eight eyes were treated with combined PDT and sub-tenon injection of 20 mg TA and compared with a control group of 49 eyes treated with PDT alone. All patients completed 1 year follow-up. The main outcome measures were best-corrected visual acuity (BCVA) and retreatment frequency.
  
  
  RESULTS
  There were no significant differences in age, sex, VA, lesion type, and greatest linear dimension between the two groups at baseline. BCVA analysis showed statistically no significant differences between the two groups. The PDT+TA group required a lower mean number of treatments (1.38 versus 1.67, P=0.032).
  
  
  CONCLUSIONS
  Our study confirms that sub-Tenon's capsule injection of TA with PDT significantly reduces the retreatment frequency of PDT.
authors.affiliation: Department of Ophthalmology, Institute of Health Biosciences, the University of Tokushima Graduate School, Tokushima, Japan.
authors.forename: Takashi
authors.initials: T
authors.lastname: Katome
authors.forename: Takeshi
authors.initials: T
authors.lastname: Naito
authors.forename: Toshihiko
authors.initials: T
authors.lastname: Nagasawa
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Shiota
mesh_terms: D000368:Aged; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage*; D003131:Combined Modality Therapy; D003238:Connective Tissue / Q000187:drug effects; D005260:Female; D006801:Humans; D008268:Macular Degeneration / Q000188:drug therapy* / Q000503:physiopathology; D008297:Male; D010778:Photochemotherapy; D017319:Photosensitizing Agents / Q000627:therapeutic use; D011166:Porphyrins / Q000627:therapeutic use; D014222:Triamcinolone Acetonide / Q000008:administration & dosage*; D000077362:Verteporfin; D014792:Visual Acuity / Q000187:drug effects
chemical_list: D000893:Anti-Inflammatory Agents; D017319:Photosensitizing Agents; D011166:Porphyrins; D000077362:Verteporfin; D014222:Triamcinolone Acetonide